{"id":551,"date":"2024-02-25T00:56:40","date_gmt":"2024-02-24T23:56:40","guid":{"rendered":"https:\/\/www.institut-athos.at\/?page_id=551"},"modified":"2024-03-31T12:13:30","modified_gmt":"2024-03-31T10:13:30","slug":"therapie","status":"publish","type":"page","link":"https:\/\/www.institut-athos.at\/en\/therapie\/","title":{"rendered":"Therapy"},"content":{"rendered":"
\n\n\n

Nourishment<\/h3>\n\n\n\n
\n
\n

After a nutritional protocol has been established, it is easy to identify the “sins” and to develop a modification of the lifestyle.<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n\n\n\n\n

Medicinal<\/h3>\n\n\n\n
\n
\n

If sufficient nutritional change is not sufficient to reach the appropriate target values (table), additional (combination) drug therapy is required.<\/p>\n\n\n\n

If a vascular event has already occurred, the drug therapy must be initiated
immediately and maintained for a period of time (under regular control).<\/p>\n\n\n\n

arget values of lipid therapy<\/strong><\/strong><\/p>\n\n\n\n

Parameter<\/td>Prevention<\/td>Therapy<\/td><\/tr>
CH<\/td>< 200<\/td>< 160<\/td><\/tr>
HDL<\/td>> 50<\/td>> 50<\/td><\/tr>
LDL\u00b2<\/td>< 130<\/td>< 100<\/td><\/tr>
CH\/HDL<\/td>< 5<\/td>< 3<\/td><\/tr>
TG<\/td>< 200<\/td>< 200<\/td><\/tr>
Lp(a)<\/td>< 30<\/td>< 30<\/td><\/tr>
non-HDL-CH*\u00b2<\/td>< 160<\/td>< 130<\/td><\/tr>
non HDL-Lp**\u00b2<\/td>< 190<\/td>< 160<\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n\n\n\n
\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n

CH = Cholesterol;
HDL = high-density Lipoprotein;
LDL = low-density Lipoprotein;
TG= Triglyceride;
Lp(a) = Lipoprotein(a);
all limits (except CH\/HDL) in mg\/dl;
CH: 1 mmol\/l = 38.7 mg\/dl;
TG: 1 mmol\/l = 88.6 mg\/dl;<\/p>\n\n\n\n

* non-HDL-Cholesterol (Cholesterol \u2013 HDL cholesterol) is easier and cheaper to calculate than LDL cholesterol for risk assessment (assessment of a future vascular event or death);<\/p>\n\n\n\n

** the inclusion of Lp (a) for which a value of max. 30 mg \/ dl is the best way to take into account the risk of increased Lp (a) for the therapy decision;<\/p>\n\n\n\n

\u00b9optimal: < 150; \u00b230-er Regel (Differenz Prim\u00e4r- vs. Sekund\u00e4rpr\u00e4vention)ptimal: < 150; \u00b230 Rule (Difference between primary and secondary prevention)<\/p>\n\n\n\n\n\n\n\n

Lipoprotein Apheresis<\/h3>\n\n\n\n
\n
\n

In those patients (extremely rare cases) who are unable to achieve the appropriate target values with a dietary and combined drug therapy, lipoproteinapheresis (blood wash) is required.<\/p>\n\n\n\n

<\/p>\n\n\n\n

This is usually done at weekly intervals at specialized centers, such as: at ATHOS.<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n
WEITER ZU:<\/h5>\n\n\n\n